The report offers new insights into the limits of the BCL2 inhibitor among patients who have myelodysplastic syndromes. A new report explains why patients with myelodysplastic syndromes (MDS) become ...

Researchers at Moffitt Cancer Center and colleagues at six other institutions have recently tested a treatment for patients with myelodysplastic syndrome, or MDS, a blood-related malignancy that ...

Distinguishing myelodysplastic syndrome (MDS) from acute myeloid leukemia (AML) solely on the basis of a 20% bone marrow blast cutoff ignores important patient characteristics and genetic factors that ...

Patients with histories of inflammatory bowel disease and systemic lupus erythematosus were also at elevated risks of myelodysplastic syndromes (MDS), the authors found. A new report shows that ...

An expert explained the burden that red blood cell transfusions can place on patients with MDS. Among patients with myelodysplastic syndromes (MDS), treatment with Reblozyl (luspatercept) resulted in ...